INmune Bio Reports Q3 GAAP EPS of -$0.17, Missing Estimates by $0.02
INmune Bio (INMB) reported third-quarter financial results featuring a GAAP earnings per share (EPS) of -$0.17, which fell short of market expectations by $0.02. The company's liquidity position remains a key focus for investors, reporting approximately $16.3 million in cash and cash equivalents as of September 30, 2024. Despite the earnings miss, the company continues to advance its clinical pipeline, including research into XPro for Alzheimer's disease through collaborations involving quantum computing technologies. Recent capital activities include a $4.5 million registered direct offering and private placement aimed at supporting ongoing operations.
Tickers: $INMB
Topics: cash position earnings report EPS miss stock price movement